Clinical trials: insulin glargine
Diabetes, Surgery
Perioperative Insulin Glargine Dosing Study
The main objective of this study is to compare three strategies of evening insulin glargine dosing to preoperative glucose values in patients with diabetes undergoing surgery to determine which dosing strategies most often…
- Trial name
- NCT00309465
- Testing
- Lantus, Insulin
- Where
- 2 sites in United States
- Volunteers
- 402 people
- Sponsor
- Tamra Dukatz
Diabetes Mellitus, Type 2
A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes
The main purpose of this study is to evaluate the use of the study drug known as dulaglutide in participants with type II diabetes who are taking once-daily insulin glargine.
- Trial name
- AWARD-9 (NCT02152371)
- Testing
- Dulaglutide, Insulin Glargine, Metformin
- Where
- 40 sites in United States, Czechia and 5 more
- Volunteers
- 300 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type II
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus
The purpose of the study was to compare Humalog (insulin lispro)-recombinant human hyaluronidase PH20 (rHuPH20) or Novolog (insulin aspart)-rHuPH20 to insulin lispro for the treatment of Type 2 diabetes mellitus (T2DM) in…
- Trial name
- NCT01194258
- Testing
- Insulin lispro, Insulin aspart, Recombinant human hyaluronidase PH20
- Where
- 22 sites in United States
- Volunteers
- 132 people
- Sponsor
- Halozyme Therapeutics
Diabetes Mellitus, Type 2
Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide
This study will compare insulin lispro protamine suspension (ILPS) and insulin glargine in combination with the patient's oral diabetes medications and exenatide, for their ability to control blood sugar in patients with type 2…
- Trial name
- NCT00560417
- Testing
- Insulin Lispro Protamine Suspension, Insulin Glargine
- Where
- 52 sites in United States, Puerto Rico
- Volunteers
- 339 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes
Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes
In this pilot study we are evaluating the efficacy of pramlintide on preventing weight gain among early onset type 1 diabetes. We are also evaluating the safety and the effects of treatment with pramlintide on early diagnosed…
- Trial name
- NCT00505882
- Testing
- Pramlintide, Glargine, Lispro
- Where
- United States
- Sponsor
- University of Texas Southwestern Medical Center
Diabetes Mellitus, Type 2
Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients
To compare the progression of diabetic retinopathy in type 2 diabetic patients with mild-to-moderate diabetic retinopathy treated with insulin glargine vs NPH human insulin.
- Trial name
- NCT00174824
- Testing
- Insulin glargine
- Where
- 2 sites in United States, Canada
- Volunteers
- 1,024 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Insulin Glulisine in Diabetes Mellitus, Type 2
Primary objective: The primary study objective is to demonstrate superior efficacy of an intensified insulin regimen with insulin glulisine and insulin glargine to a two-injection conventional insulin regimen in terms of change…
- Trial name
- GINGER (NCT00174668)
- Testing
- Insulin Glulisine, Insulin Therapy, Insulin Glargine
- Where
- 15 sites in Australia, Belgium and 13 more
- Volunteers
- 311 people
- Sponsor
- Sanofi
Diabetes Mellitus Type 2, Hospitalization
Effect of the Use of Continuous Glucose Monitoring Versus Standard Glycemic Control in Hospitalized Patients with Type 2 Diabetes.
Type 2 diabetes (T2D) is a common pathology in hospitalized patients and is associated with multiple comorbidities. Moreover, it is widely known that glycemic excursions increase hospital stay, infections, morbidity and…
- Trial name
- NCT06607224
- Testing
- Experimental (Decision making guided by CGM)
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
Type2 Diabetes
Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan
This is a study to be performed in Qatar that will look at the comparison of glycemic control in patients with type 2 diabetes on insulin glargine U100 with insulin degludec over the Ramadan period, to determine whether better…
- Trial name
- NCT03349840
- Testing
- Insulin Degludec U100, Insulin Glargine
- Where
- Qatar
- Volunteers
- 273 people
- Sponsor
- Weill Cornell Medical College in Qatar
Type 2 Diabetes
Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients
Primary objective: To evaluate the effect of lixisenatide versus placebo over a period of 24 weeks on glycemic control, as evaluated by glycosylated hemoglobin (HbA1c) reduction, in older type 2 diabetes participants (T2DM) who…
- Trial name
- GetGoal-O (NCT01798706)
- Testing
- Lixisenatide (AVE0010), Antidiabetic background therapy
- Where
- 83 sites in United States, Australia and 11 more
- Volunteers
- 350 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).
This is an efficacy and safety study of ertugliflozin in participants with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on metformin monotherapy.
- Trial name
- NCT02033889
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 15 mg, Glimepiride
- Volunteers
- 621 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Venous Disease, Varicose Ulcer
Effects of Local Insulin on Varicose Ulcers for Wound Healing
A randomized, split-plot, double-blind, placebo-controlled trial. The varicose ulcer is divided into two (side A and B). Half of the wound's surface is treated locally with insulin (Glargine) applied at an approx depth of 3-4 mm.
- Conditions
- Chronic Venous Disease, Varicose Ulcer, Wound Healing, Insulin
- Trial name
- NCT04310280
- Testing
- Insulin Glargine, Saline
- Where
- Mexico
- Volunteers
- 13 people
- Sponsor
- Hospital Central "Dr. Ignacio Morones Prieto"
Type 2 Diabetes Mellitus
Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin
Primary Objective: To demonstrate the superiority of iGlarLixi (fixed ratio combination of insulin glargine and lixisenatide) to insulin glargine on glycemic control as assessed by glycated hemoglobin A1c (HbA1c) change in…
- Trial name
- Lixilan-L-CN (NCT03798080)
- Testing
- Insulin glargine/Lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Metformin
- Where
- 45 sites in China
- Volunteers
- 426 people
- Sponsor
- Sanofi
Diabetes, Type 2
A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes
This study compares insulin icodec, a new insulin taken once a week, to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 2 diabetes.
- Trial name
- NCT06340854
- Testing
- Insulin icodec, Insulin glargine
- Where
- 83 sites in United States, Bulgaria and 7 more
- Volunteers
- 412 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
This trial is conducted in Africa, Asia, Europe and South America. This trial is designed to show the effect of treatment with liraglutide added to existing glimepiride and metformin combination therapy and to compare it with the…
- Trial name
- LEAD-5 (NCT00331851)
- Testing
- liraglutide, insulin glargine, metformin
- Where
- 116 sites in Argentina, Austria and 16 more
- Volunteers
- 584 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat Type 2 Diabetes
In recent years, with the further research of the pathogenesis of diabetes mellitus and the mechanism of oral antidiabetes drugs, the early combination therapy of oral antidiabetes drugs and insulin is getting paid more and more…
- Trial name
- CODMS (NCT00736515)
- Testing
- Gliclazide MR and Insulin Glargine Injection, Biosynthetic Human Insulin Injection
- Where
- 8 sites in China
- Volunteers
- 160 people
- Sponsor
- Servier (Tianjin) Pharmaceutical Co. LTD.
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
This trial was conducted in Europe and North America. The aim of this clinical trial was to compare NN1250 (insulin degludec (IDeg)), a soluble insulin basal analogue (SIBA), with insulin glargine (IGlar), as add-on to subject's…
- Trial name
- BEGIN™ (NCT01076647)
- Testing
- insulin degludec, insulin glargine
- Where
- 105 sites in United States, Bulgaria and 5 more
- Volunteers
- 467 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Cost Effectiveness of Glargine Insulin Versus NPH Insulin
Glycemic control is fundamental in the management of diabetes mellitus .If lifestyle intervention and full tolerated doses of one or two oral glucose lowering drugs (OGLDs) fail to achieve or sustain glycemic goals, insulin…
- Trial name
- NCT01832935
- Testing
- insulin glargine, Insulin NPH
- Where
- Iran
- Volunteers
- 200 people
- Sponsor
- Tehran University of Medical Sciences
Diabetic Ketoacidosis, Type 1 Diabetes
Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management
Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management
- Conditions
- Diabetic Ketoacidosis, Type 1 Diabetes, Type 2 Diabetes
- Trial name
- NCT04567225
- Testing
- Early Glargine, Late Glargine, IV insulin infusion
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- The Cleveland Clinic
Diabetes Mellitus, Type 2
Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy
This study aimed to evaluate the long-term effectiveness and safety of the empagliflozin as add-on thearpy compared to basal insulin-based antidiabetic agents (OADs) combination therapy in patients with type 2 diabetes…
- Trial name
- LUCID (NCT05103306)
- Testing
- Empagliflozin 25 MG, INS
- Volunteers
- 300 people
- Sponsor
- Chungbuk National University Hospital